About Careers Internship MedBlog Contact us

HIV Integrase Inhibitor: The New Revolutionary Anti-AIDS Medication

by Hannah Punitha on October 28, 2008 at 3:23 PM
 HIV Integrase Inhibitor: The New Revolutionary Anti-AIDS Medication

Medical researchers on Sunday unveiled clinical trials of new anti-AIDS drug that better controls the spread of the deadly virus among previously untreated patients.

Developed by US pharmaceutical giant Merck and Co, Isentress is the first of a new type of anti-AIDS medication called HIV integrase inhibitor, based on the enzyme that controls HIV virus reproduction.


The study's Phase III clinical trials -- the last step before an approval request can be submitted to the Food and Drug Administration (FDA) -- showed Isentress reduced HIV viral load to undetectable levels in 86 percent of patients, against only 82 percent treated with efavirenz, an older anti-HIV medication also developed by Merck.

Drug-related adverse effects were also significantly fewer in patients treated with Isentress (44 percent) than with efavirenz (77 percent), the researchers told the 48th annual Interscience Conference on Antimicrobial Agents held this weekend in Washington.

Patients taking part in the clinical trial also took tenofovir and emtricitabine in combination with Isentress and efavirenz, Merck said in a statement.

On October 12, 2007, the FDA granted Isentress accelerated approval for use with patients that showed initial signs of resistance to existing anti-retroviral treatment, a common problem among AIDS patients.

Merck estimates that among some 500,000 US patients treated with anti-HIV cocktails, up to 40 percent have developed resistance to treatment.

Industry analysts said treatment with Isentress pills twice a day could bring Merck one billion dollars in sales over the next three years, competing directly with rival Gilead Sciences' elvitegravir, also undergoing clinical trials.

A separate study presented at the ICAAC conference showed anti-retroviral treatment was more effective if begun earlier: patients treated when CD4 cell count was at 500 had a 71 percent greater risk of dying than those treated when CD4 levels reached 350.

According to the World Health Organization, 33 million people around the world are infected with the AIDS virus, mostly in the sub-Sahara Africa. One million HIV-infected people live in the United States.

Some two million people died worlwide of AIDS in 2007.

Source: AFP
Font : A-A+



Recommended Readings

Latest AIDS/HIV News

Beauty Salon-Driven Initiative Boosts PrEP Awareness in Fight Against AIDS
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Immune-Evading HIV Protein Complex Solved
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Does Gender Influence Comorbidity Rates in HIV-Positive Smokers
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.
Digital Test Measures HIV Viral Load
DNA editing tool CRISPR-Cas13 helps diagnose and signal the presence of HIV antibodies in HIV patients.
New Era of HIV Testing Expanded by INVEX Health
INVEX Health, headquartered in Mumbai, has unveiled its forthcoming release of India's premier oral HIV self-test.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

HIV Integrase Inhibitor: The New Revolutionary Anti-AIDS Medication Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests